Eltrombopag named patient programme for patients with chronic immune thrombocytopenia

被引：2

作者：

Scully, Maria ^{[1
]}

Kaczmarski, Richard ^{[2
]}

Myers, Bethan ^{[3
]}

Collins, Rod ^{[4
]}

Emohare, Osa ^{[5
]}

Bolton-Maggs, Paula H. B. ^{[6
,7
]}

机构：

[1] UCLH, Dept Haematol, London, England

[2] Hillingdon Hosp, Dept Haematol, London, England

[3] Queens Med Ctr, Dept Haematol, Nottingham NG7 2UH, England

[4] Chesterfield Royal Hosp, Dept Haematol, Chesterfield, Derby, England

[5] GlaxoSmithKline Inc, Uxbridge, Middx, England

[6] Univ Manchester, Manchester, Lancs, England

[7] Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷 / 02期

关键词：

eltrombopag; chronic immune thrombocytopenia; CELL-DEPLETING THERAPY; PURPURA; ADULTS; RITUXIMAB;

D O I：

10.1111/j.1365-2141.2011.08954.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：259 / 260

页数：2

共 10 条

[1] BERCHTOLD P, 1989, BLOOD, V74, P2309
[2] Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
Bussel, James B.
Cheng, Gregory
Saleh, Mansoor N.
Psaila, Bethan
Kovaleva, Lidia
Meddeb, Balkis
Kloczko, Janusz
Hassani, Habib
Mayer, Bhabita
Stone, Nicole L.
Arning, Michael
Provan, Drew
Jenkins, Julian M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) : 2237 - 2247
[3] Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
Bussel, James B.
Provan, Drew
Shamsi, Tahir
Cheng, Gregory
Psaila, Bethan
Kovaleva, Lidia
Salama, Abdulgabar
Jenkins, Julian M.
Roychowdhury, Debasish
Mayer, Bhabita
Stone, Nicole
Arning, Michael
[J]. LANCET, 2009, 373 (9664) : 641 - 648
[4] Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
Cheng, Gregory
Saleh, Mansoor N.
Marcher, Claus
Vasey, Sandra
Mayer, Bhabita
Aivado, Manuel
Arning, Michael
Stone, Nicole L.
Bussel, James B.
[J]. LANCET, 2011, 377 (9763) : 393 - 402
[5] Therapy for adults with refractory chronic immune thrombocytopenic purpura
McMillan, R
[J]. ANNALS OF INTERNAL MEDICINE, 1997, 126 (04) : 307 - 314
[6] Morbidity and mortality in adults with idiopathic thrombocytopenic purpura
Portielje, JEA
Westendorp, RGJ
Kluin-Nelemans, HC
Brand, A
[J]. BLOOD, 2001, 97 (09) : 2549 - 2554
[7] Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Rodeghiero, Francesco
Stasi, Roberto
Gernsheimer, Terry
Michel, Marc
Provan, Drew
Arnold, Donald M.
Bussel, James B.
Cines, Douglas B.
Chong, Beng H.
Cooper, Nichola
Godeau, Bertrand
Lechner, Klaus
Mazzucconi, Maria Gabriella
McMillan, Robert
Sanz, Miguel A.
Imbach, Paul
Blanchette, Victor
Kuehne, Thomas
Ruggeri, Marco
George, James N.
[J]. BLOOD, 2009, 113 (11) : 2386 - 2393
[8] Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
Stasi, Roberto
Cooper, Nichola
Del Poeta, Giovanni
Stipa, Elisa
Evangelista, Maria Laura
Abruzzese, Elisabetta
Amadori, Sergio
[J]. BLOOD, 2008, 112 (04) : 1147 - 1150
[9] Novel thrombopoietic agents - A review of their use in idiopathic thrombocytopenic purpura
Stasi, Roberto
Evangelista, Maria L.
Amadori, Sergio
[J]. DRUGS, 2008, 68 (07) : 901 - 912
[10] Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
Stasi, Roberto
Del Poeta, Giovanni
Stipa, Elisa
Evangelista, Maria Laura
Trawinska, Margherita M.
Cooper, Nichola
Arnadori, Sergio
[J]. BLOOD, 2007, 110 (08) : 2924 - 2930

← 1 →